GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » Cyclically Adjusted Revenue per Share

GSK (GSK) Cyclically Adjusted Revenue per Share : $21.15 (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is GSK Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Mar. 2024 was $4.549. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $21.15 for the trailing ten years ended in Mar. 2024.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 8.90% per year. The lowest was 0.60% per year. And the median was 5.05% per year.

As of today (2024-06-06), GSK's current stock price is $41.97. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $21.15. GSK's Cyclically Adjusted PS Ratio of today is 1.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.70. The lowest was 1.57. And the median was 2.10.


GSK Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.52 20.85 21.49 20.09 21.39

GSK Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.59 21.45 20.36 21.39 21.15

Competitive Comparison of GSK's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.



GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.549/131.6000*131.6000
=4.549

Current CPI (Mar. 2024) = 131.6000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.826 99.800 6.364
201409 4.725 100.000 6.218
201412 5.031 99.900 6.627
201503 4.322 99.600 5.711
201506 4.704 100.100 6.184
201509 4.817 100.200 6.327
201512 4.769 100.400 6.251
201603 4.536 100.400 5.946
201606 4.774 101.000 6.220
201609 5.054 101.500 6.553
201612 4.776 102.200 6.150
201703 4.634 102.700 5.938
201706 4.795 103.500 6.097
201709 5.298 104.300 6.685
201712 5.150 105.000 6.455
201803 5.099 105.100 6.385
201806 4.899 105.900 6.088
201809 5.319 106.600 6.566
201812 5.203 107.100 6.393
201903 5.069 107.000 6.234
201906 4.958 107.900 6.047
201909 5.799 108.400 7.040
201912 5.761 108.500 6.988
202003 5.614 108.600 6.803
202006 4.749 108.800 5.744
202009 5.555 109.200 6.694
202012 -0.670 109.400 -0.806
202103 5.106 109.700 6.125
202106 4.055 111.400 4.790
202109 4.491 112.400 5.258
202112 4.634 114.700 5.317
202203 4.660 116.500 5.264
202206 3.360 120.500 3.670
202209 4.338 122.300 4.668
202212 4.393 125.300 4.614
202303 4.130 126.800 4.286
202306 3.543 129.400 3.603
202309 4.904 130.100 4.961
202312 4.948 130.500 4.990
202403 4.549 131.600 4.549

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GSK  (NYSE:GSK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.97/21.15
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.70. The lowest was 1.57. And the median was 2.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (GSK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » Cyclically Adjusted Revenue per Share
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.